UnknownNot Applicable

ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or

100 participantsStarted 2021-01-18

Plain-language summary

Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * hepatocellular carcinoma locally advanced or metastatic, non able to be resectable, with no prior systemic treatment * Child Pugh A and ECOG 0 or 1 * upper digestiuve endoscopy less than 6 months, if esophageal varcices : must be treated * non eligible to receive a locoregional therpay or progressive after this kinf of treatment * with informed consent Exclusion Criteria: * refuse to participate * under legal protection * exclusion criteria from the tempory utilisation authorization

What they're measuring

predictive factor for progression-free survival

Timeframe: 12 months

Trial details

NCT IDNCT04730388

SponsorUniversity Hospital, Brest

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-01-18

Contact for this trial

Pierre-Guillaume Poureau, MD

0298223740 pierre-guillaume.poureau@chu-brest.fr

View on ClinicalTrials.gov More Advanced Hepatocellular Carcinoma trials